Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SABS SAB Biotherapeutics Inc
- Stocks
- Healthcare
- NASDAQ: SABS
Price (delayed)
$1.96
Market cap
$18.21M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.7
Enterprise value
$19.35M
Highlights
The EPS has increased by 45% YoY
SAB Biotherapeutics's net income has increased by 14% YoY
SAB Biotherapeutics's revenue has shrunk by 85% YoY and by 71% QoQ
SAB Biotherapeutics's gross profit has shrunk by 85% YoY and by 71% QoQ
Key stats
What are the main financial stats of SABS
Market
Valuations
Earnings
Shares outstanding
9.29M
Market cap
$18.21M
Enterprise value
$19.35M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.85
Price to sales (P/S)
48.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
51.22
Revenue
$377,835
Gross profit
$377,835
Operating income
-$42.29M
Net income
-$34.28M
EBIT
-$33.96M
EBITDA
-$30.38M
Free cash flow
-$31.55M
Per share
Balance sheet
Liquidity
EPS
-$3.7
EPS diluted
-$3.7
Free cash flow per share
-$3.4
Book value per share
$2.3
Revenue per share
$0.04
TBVPS
$4.1
Total assets
$38.12M
Total liabilities
$16.71M
Debt
$6.78M
Equity
$21.41M
Working capital
$6.64M
Debt to equity
0.32
Current ratio
1.69
Quick ratio
1.33
Net debt/EBITDA
-0.04
Margins
Efficiency
Dividend
EBITDA margin
-8,040.2%
Gross margin
100%
Net margin
-9,071.8%
Operating margin
-11,193.2%
Return on assets
-69.2%
Return on equity
-105.1%
Return on invested capital
-94.1%
Return on capital employed
-119.3%
Return on sales
-8,989.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SABS stock price
How has the SAB Biotherapeutics stock price performed over time
Intraday
13.95%
1 week
11.68%
1 month
8.29%
1 year
-31.71%
YTD
-48.34%
QTD
11.68%
Financial performance
How have SAB Biotherapeutics's revenue and profit performed over time
Revenue
$377,835
Gross profit
$377,835
Operating income
-$42.29M
Net income
-$34.28M
Gross margin
100%
Net margin
-9,071.8%
SAB Biotherapeutics's revenue has shrunk by 85% YoY and by 71% QoQ
SAB Biotherapeutics's gross profit has shrunk by 85% YoY and by 71% QoQ
SAB Biotherapeutics's net income has increased by 14% YoY
Price vs fundamentals
How does SABS's price correlate with its fundamentals
Growth
What is SAB Biotherapeutics's growth rate over time
Valuation
What is SAB Biotherapeutics stock price valuation
P/E
N/A
P/B
0.85
P/S
48.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
51.22
The EPS has increased by 45% YoY
The P/B is 67% below the 5-year quarterly average of 2.6 but 6% above the last 4 quarters average of 0.8
SAB Biotherapeutics's equity has shrunk by 59% YoY and by 18% QoQ
The P/S is 122% above the last 4 quarters average of 21.7
SAB Biotherapeutics's revenue has shrunk by 85% YoY and by 71% QoQ
Efficiency
How efficient is SAB Biotherapeutics business performance
SAB Biotherapeutics's ROIC has increased by 29% YoY but it has decreased by 18% from the previous quarter
The ROE has contracted by 25% from the previous quarter but it has grown by 4.4% YoY
SABS's ROA is down by 17% from the previous quarter but it is up by 4.9% YoY
Dividends
What is SABS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SABS.
Financial health
How did SAB Biotherapeutics financials performed over time
The company's total assets is 128% higher than its total liabilities
The quick ratio has plunged by 75% YoY and by 49% from the previous quarter
SABS's current ratio has dropped by 70% year-on-year and by 43% since the previous quarter
The company's debt is 68% lower than its equity
SABS's debt to equity has soared by 78% since the previous quarter
SAB Biotherapeutics's equity has shrunk by 59% YoY and by 18% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.